BR112015010109A2 - derivados de indol-5-ol substituídos e suas aplicações terapêuticas - Google Patents

derivados de indol-5-ol substituídos e suas aplicações terapêuticas

Info

Publication number
BR112015010109A2
BR112015010109A2 BR112015010109A BR112015010109A BR112015010109A2 BR 112015010109 A2 BR112015010109 A2 BR 112015010109A2 BR 112015010109 A BR112015010109 A BR 112015010109A BR 112015010109 A BR112015010109 A BR 112015010109A BR 112015010109 A2 BR112015010109 A2 BR 112015010109A2
Authority
BR
Brazil
Prior art keywords
derivatives
therapeutic applications
substituted indol
indol
diseases
Prior art date
Application number
BR112015010109A
Other languages
English (en)
Inventor
Tao Chunlin
Ho David
Nallan Laxman
Soon-Shiong Patrick
Wang Qinwei
Polat Tulay
Original Assignee
Nant Holdings Ip Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nant Holdings Ip Llc filed Critical Nant Holdings Ip Llc
Publication of BR112015010109A2 publication Critical patent/BR112015010109A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

resumo derivados de indol-5-ol substituídos e suas aplicações terapêuticas a presente invenção refere-se genericamente à utilização de compostos para tratar uma variedade de distúrbios, doenças e condições patológicas e, mais especificamente, à utilização de derivados de indol-5-ol substituídos para modular proteínas cinases e para o tratamento de doenças mediadas por cinase de proteína.
BR112015010109A 2012-11-05 2013-11-05 derivados de indol-5-ol substituídos e suas aplicações terapêuticas BR112015010109A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261722537P 2012-11-05 2012-11-05
US201361852309P 2013-03-15 2013-03-15
PCT/US2013/068515 WO2014071378A1 (en) 2012-11-05 2013-11-05 Substituted indol-5-ol derivatives and their therapeutical applications

Publications (1)

Publication Number Publication Date
BR112015010109A2 true BR112015010109A2 (pt) 2017-07-11

Family

ID=50628164

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015010109A BR112015010109A2 (pt) 2012-11-05 2013-11-05 derivados de indol-5-ol substituídos e suas aplicações terapêuticas

Country Status (11)

Country Link
US (2) US9458137B2 (pt)
EP (1) EP2914265A4 (pt)
JP (1) JP6277198B2 (pt)
KR (1) KR20150104089A (pt)
CN (1) CN104955459B (pt)
AU (1) AU2013337297A1 (pt)
BR (1) BR112015010109A2 (pt)
CA (1) CA2890018A1 (pt)
IL (1) IL238553B (pt)
RU (1) RU2674249C2 (pt)
WO (1) WO2014071378A1 (pt)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2914265A4 (en) 2012-11-05 2016-04-13 Nant Holdings Ip Llc SUBSTITUTED INDOL-5-OL COMPOUNDS AND THEIR THERAPEUTIC APPLICATIONS
AU2014233069A1 (en) * 2013-03-15 2015-09-24 Nantbioscience, Inc. Substituted indol-5-ol derivatives and their therapeutic applications
CN110444289A (zh) * 2013-06-28 2019-11-12 南托米克斯有限责任公司 用于诊断检测的识别的途径分析
CN112279808B (zh) 2014-10-06 2024-03-08 弗特克斯药品有限公司 囊性纤维化跨膜转导调节因子调节剂
CN107708690B (zh) * 2015-02-27 2021-09-14 常山凯捷健生物药物研发（河北）有限公司 作为激酶抑制剂的嘧啶衍生物和它们的治疗应用
RU2625749C2 (ru) * 2015-03-31 2017-07-18 Автономная Некоммерческая Организация "Научно-Исследовательский Центр Биотехнологии Антибиотиков И Других Биологически Активных Веществ "Биоан" Применение rac-N-{ 4-[(2-этокси-3-октадецилокси)пропил]оксикарбонилбутил} -N-метил-имидазолинийиодида в качестве мультикиназного ингибитора
WO2017173274A1 (en) 2016-03-31 2017-10-05 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
PE20191147A1 (es) 2016-09-30 2019-09-02 Vertex Pharma Modulador de regulador de conductancia de transmembrana de fibrosis quistica, composiciones farmaceuticas, metodos de tratamiento y proceso para producir el modulador
UY37513A (es) 2016-12-09 2018-07-31 Vertex Pharma Modulador del regulador de conductancia transmembrana de fibrosis quística, composiciones farmacéuticas, métodos de tratamiento y proceso para producir el modulador
US10800760B2 (en) 2017-05-31 2020-10-13 Nantbio, Inc. Trk inhibition
US10738033B2 (en) 2017-05-31 2020-08-11 Nantbio, Inc. Trk inhibition
BR112019025801A2 (pt) 2017-06-08 2020-07-07 Vertex Pharmaceuticals Incorporated métodos de tratamento para fibrose cística
EP3654969A1 (en) 2017-07-17 2020-05-27 Vertex Pharmaceuticals Incorporated Methods of treatment for cystic fibrosis
AU2018309043B2 (en) 2017-08-02 2022-03-31 Vertex Pharmaceuticals Incorporated Processes for preparing pyrrolidine compounds
WO2019079760A1 (en) 2017-10-19 2019-04-25 Vertex Pharmaceuticals Incorporated CRYSTALLINE FORMS AND COMPOSITIONS OF CFTR MODULATORS
KR20200097293A (ko) 2017-12-08 2020-08-18 버텍스 파마슈티칼스 인코포레이티드 낭포성 섬유증 막횡단 전도 조절자의 조정제의 제조 방법
TWI810243B (zh) 2018-02-05 2023-08-01 美商維泰克斯製藥公司 用於治療囊腫纖化症之醫藥組合物
EP3774825A1 (en) 2018-04-13 2021-02-17 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5916596A (en) 1993-02-22 1999-06-29 Vivorx Pharmaceuticals, Inc. Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
US6537579B1 (en) 1993-02-22 2003-03-25 American Bioscience, Inc. Compositions and methods for administration of pharmacologically active compounds
US6096331A (en) 1993-02-22 2000-08-01 Vivorx Pharmaceuticals, Inc. Methods and compositions useful for administration of chemotherapeutic agents
AR016294A1 (es) * 1997-07-02 2001-07-04 Smithkline Beecham Corp Compuesto de imidazol sustituido, composicion farmaceutica que la contiene, su uso en la fabricacion de un medicamento y procedimiento para supreparacion
JP2001519381A (ja) * 1997-10-10 2001-10-23 インペリアル・カレッジ・イノベイションズ・リミテッド 子宮収縮管理のためのｃｓａｉｄｔｍ化合物の使用
KR20080015482A (ko) 1999-02-10 2008-02-19 아스트라제네카 아베 혈관형성 억제제로서의 퀴나졸린 유도체
US6703420B1 (en) 1999-03-19 2004-03-09 Bristol-Myers Squibb Pharma Company Amino-thio-acrylonitriles as MEK inhibitors
US20070117785A1 (en) 2000-08-14 2007-05-24 Butler Christopher R Substituted pyrazoles and methods of treatment with substituted pyrazoles
RU2317988C2 (ru) 2000-08-14 2008-02-27 Орто-Макнейл Фармасьютикал, Инк. Замещенные пиразолы, фармацевтическая композиция на их основе, применение фармацевтической композиции и способ ингибирования активности катепсина s
ATE324372T1 (de) 2000-08-14 2006-05-15 Ortho Mcneil Pharm Inc Substituierte pyrazole
US20050101587A9 (en) 2000-08-14 2005-05-12 Butler Christopher R. Method for treating allergies using substituted pyrazoles
RU2278863C2 (ru) 2001-08-10 2006-06-27 Орто-Макнейл Фармасьютикал, Инк. Замещенные пиразолы, фармацевтическая композиция и способ ингибирования активности катепсина s
MY141867A (en) * 2002-06-20 2010-07-16 Vertex Pharma Substituted pyrimidines useful as protein kinase inhibitors
CN101012200A (zh) * 2002-06-20 2007-08-08 沃泰克斯药物股份有限公司 制备作为蛋白激酶抑制剂的取代的嘧啶和嘧啶衍生物的方法
TWI272271B (en) 2002-07-19 2007-02-01 Bristol Myers Squibb Co Process for preparing certain pyrrolotriazine compounds
JP4183193B2 (ja) * 2002-08-30 2008-11-19 エーザイ・アール・アンド・ディー・マネジメント株式会社 含窒素芳香環誘導体
US7078419B2 (en) * 2003-03-10 2006-07-18 Boehringer Ingelheim Pharmaceuticals, Inc. Cytokine inhibitors
PE20060437A1 (es) * 2004-06-18 2006-06-08 Novartis Ag COMPUESTOS AZA-BICICLONONANOS COMO LIGANDOS COLINERGICOS DE nAChR
GB0415746D0 (en) * 2004-07-14 2004-08-18 Novartis Ag Organic compounds
ATE519759T1 (de) * 2004-12-30 2011-08-15 Exelixis Inc Pyrimidinderivate als kinasemodulatoren und anwendungsverfahren
US7713960B2 (en) 2005-07-22 2010-05-11 University Of South Florida Inhibition of the Raf/Mek/P-Erk pathway for treating cancer
US20090149467A1 (en) * 2005-09-15 2009-06-11 Merck & Co., Inc. Tyrosine Kinase Inhibitors
EP1783114A1 (en) * 2005-11-03 2007-05-09 Novartis AG N-(hetero)aryl indole derivatives as pesticides
NZ594385A (en) * 2005-11-03 2013-02-22 Vertex Pharma Aminopyrimidines useful as kinase inhibitors
US8013153B2 (en) * 2006-03-23 2011-09-06 Janssen Pharmaceutica, N.V. Substituted pyrimidine kinase inhibitors
DK2154967T5 (en) * 2007-04-16 2014-11-17 Hutchison Medipharma Entpr Ltd Pyriminderivater
TW200922590A (en) 2007-09-10 2009-06-01 Curis Inc VEGFR inhibitors containing a zinc binding moiety
WO2010009342A2 (en) 2008-07-16 2010-01-21 Pharmacyclics, Inc. Inhibitors of bruton's tyrosine kinase for the treatment of solid tumors
AU2010259023A1 (en) * 2009-06-08 2012-01-12 Nantbioscience, Inc. Triazine derivatives and their therapeutical applications
EP2914265A4 (en) 2012-11-05 2016-04-13 Nant Holdings Ip Llc SUBSTITUTED INDOL-5-OL COMPOUNDS AND THEIR THERAPEUTIC APPLICATIONS
AU2014233069A1 (en) 2013-03-15 2015-09-24 Nantbioscience, Inc. Substituted indol-5-ol derivatives and their therapeutic applications
CN110444289A (zh) * 2013-06-28 2019-11-12 南托米克斯有限责任公司 用于诊断检测的识别的途径分析

Also Published As

Publication number Publication date
AU2013337297A1 (en) 2015-05-21
IL238553B (en) 2019-06-30
US10160749B2 (en) 2018-12-25
US20170088544A1 (en) 2017-03-30
CN104955459B (zh) 2019-02-01
IL238553A0 (en) 2015-06-30
WO2014071378A9 (en) 2015-02-05
CN104955459A (zh) 2015-09-30
WO2014071378A1 (en) 2014-05-08
CA2890018A1 (en) 2014-05-08
JP6277198B2 (ja) 2018-02-07
US20150291564A1 (en) 2015-10-15
KR20150104089A (ko) 2015-09-14
RU2015121431A (ru) 2016-12-27
JP2015536338A (ja) 2015-12-21
RU2674249C2 (ru) 2018-12-06
EP2914265A1 (en) 2015-09-09
EP2914265A4 (en) 2016-04-13
US9458137B2 (en) 2016-10-04

Similar Documents

Publication Publication Date Title
BR112015010109A2 (pt) derivados de indol-5-ol substituídos e suas aplicações terapêuticas
CY1121170T1 (el) Νεες ενωσεις ως ρυθμιστες πρωτεϊνικων κινασων
BR112015022307A2 (pt) derivados substituídos indol-5-ol e as suas aplicações terapêuticas
CU20160185A7 (es) Compuestos de heteroarilo para la inhibición de cinasa
EP3448389A4 (en) CHINAZOLINE AND INDOIND DERIVATIVES FOR THE TREATMENT OF MEDICAL DISORDER
CO6791571A2 (es) Moduladores de la proteína tirosina quinasa 7 (ptk7) para el tratamiento diagnóstico o profilaxis de trastornos neoplásicos
BR112014011465A2 (pt) modulação de determinadas quinases de tirosina
SG10201806849WA (en) Cyclopropylamines as lsd1 inhibitors
EP3429605A4 (en) THERAPEUTIC AGENT FOR THE TREATMENT OF DISEASES, IN PARTICULAR DISEASES AFFECTING THE CENTRAL NERVOUS SYSTEM
CO6551721A2 (es) Moduladores de cinasa novedosos
EP3212233A4 (en) Combination therapy for treatment of disease
UY39413A (es) Compuestos inhibidores de metaloenzimas
EA201691872A1 (ru) Гетероциклические соединения для применения в лечении pi3k-гамма-опосредованных расстройств
GEP20207102B (en) Sulfonamides as modulators of sodium channels
EA201590930A1 (ru) Лекарственные формы руксолитиниба с замедленным высвобождением
EA201500365A1 (ru) Комбинация регорафениба и ацетилсалициловой кислоты для лечения рака
BR112017006073A2 (pt) derivado de ácido 4-(4-(4-fenilureído-naftalen-1-il)óxi-piridin-2-il)amino-benzoico como inibidor de quinase de p38
EA201391106A1 (ru) Новые гетероциклические производные
EA201991484A1 (ru) Лекарственные формы энзалутамида
BR112014023162A8 (pt) compostos e métodos para modulação quinase e indicações dos mesmos
MX347966B (es) Derivados de quinazolina para el tratamiento de infecciones viricas y otras enfermedades.
BR112021017831A2 (pt) Derivados heteroaromáticos e aromáticos heterobicíclicos para o tratamento de distúrbios relacionados com ferroptose
BR112021026668A2 (pt) Compostos heterocíclicos como inibidores de bet
CU20160151A7 (es) 2-AMIN0-6-METI L-4,4a, 5,6-TETRAHIDROPIRANO[3,4-d][1,3]TIAZIN-8a(8H)-IL-1,3-TIAZOL-4-ILAMIDAS
UY36080A (es) Compuestos inhibidores de metaloenzima como fungicidas.

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]